PharmTech

CONTINUE TO SITE >

OR WAIT 15 SECS

COVID-19 UpdateAnalyticsDrug DevelopmentManufacturingOutsourcingQuality Systems2020 Bio/Pharma Virtual Congress

Analytical Method DevelopmentAPIsAseptic ProcessingBiologic DrugsDosage FormsDrug DeliveryEquipmentExcipientsFormulationPackagingProcess Control/PATProcess DevelopmentQA/QCRegulatory ActionSupply Chain

All NewsTop NewsIndustry NewsBio/Pharma NewsSupplier NewsNews from EuropeEvents

All PublicationsPharmTechPharmTech Europe

Front & CenterPharma InsightsSponsored eBooksSponsored PodcastsSponsored VideosWhitepapers

Webcasts Marketplace

EnewslettersMagazine North AmericaMagazine Europe

About Us
Advertise
Contact Us
Editorial Info
Editorial Contacts
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions

© 2021 MJH Life Sciences and Pharmaceutical Technology. All rights reserved.

Spotlight

COVID-19 Update
Analytics
Drug Development
Manufacturing
Outsourcing
Quality Systems
2020 Bio/Pharma Virtual Congress

Analytical Method Development
APIs
Aseptic Processing
Biologic Drugs
Dosage Forms
Drug Delivery
Equipment
Excipients
Formulation
Packaging
Process Control/PAT
Process Development
QA/QC
Regulatory Action
Supply Chain

About Us
Advertise
Contact Us
Editorial Info
Editorial Contacts
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions

© 2021 MJH Life Sciences^™ and Pharmaceutical Technology. All rights reserved.

SafeBridge - Procedure for Determining an Acceptable Daily Exposure under Risk-MaPP

October 21, 2010

SafeBridge - Procedure for Determining an Acceptable Daily Exposure under Risk-MaPP